Drug intelligence / Profile preview

Benralizumab plus Prednisolone

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Subcutaneous

Overview

The combination of benralizumab and prednisolone has been studied as a treatment approach for asthma and COPD exacerbations. Benralizumab is a monoclonal antibody that targets eosinophils, while prednisolone is a corticosteroid that has been the standard treatment for respiratory flare-ups for decades.

Targets

MR (Mineralocorticoid receptor)GR (Glucocorticoid receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IL5RA (Interleukin-5 receptor subunit alpha)

Beyond the preview

Go deeper on Benralizumab plus Prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Benralizumab plus Prednisolone.

Explore the full profile